| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a968d4ce16bddd0cd4ab7e63f09c8d3
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3201cb11df76183205b99fbe5199202
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32e28f39f58263db5783815fa90b5f25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_afb8acdeb99a4ab18faf321caaec610b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6a86291c63f245efb1eecb233329fa1e |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C311-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-277
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4858
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-4866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-38
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C311-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-18 |
| filingDate |
2020-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ed8866fb917e95d02598cb0124f49fa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62db7dbcd72a3efb339ccad8225a4b80
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a1b0eb546be402a37f1b45801d87bf27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_232f631b4f88ec1bac0af1639d5db39b |
| publicationDate |
2022-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-3988539-A1 |
| titleOfInvention |
Active ingredient, pharmaceutical composition, and medicinal preparation for therapy of hiv and aids |
| abstract |
This invention relates to the active ingredient of a pharmaceutical composition consisting of micronized monoclinic symmetry crystals (MMSCs) of sodium {[4-({[4-bromo-3-(3-chloro-5-cyanophenoxy)-2-fluorophenyl] acetyl }amino)-3-chlorophenyl] - sulfonyl}(propanoyl)azanide with an average particle diameter ≤130 µm and methods of use thereof in the treatment of Human Immunodeficiency Virus (HIV) and Acquired Immune Deficiency Syndrome (AIDS). |
| priorityDate |
2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |